TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03675438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-epitheilal TCA Inlay
Description: A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
Study: NCT03013205

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular triamcinolone injection
Description: triamcinolone 10mg/mL
Study: NCT04983784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Description: walking for 12 weeks at home
Study: NCT02743143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up care as usual
Study: NCT03013205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular triamcinolone injection
Description: triamcinolone 10mg/mL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular Xylocaine injection
Description: Xylocaine 1% 4ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular Xylocaine injection
Description: Xylocaine 1% 4ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coracohumeral ligament triamcinolone injection
Description: triamcinolone 10mg/mL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study: NCT01176019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Information about Prenatal Screening and Diagnosis
Description: 15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
Study: NCT02458092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Malaria Protein 010 (FMP010)
Description: Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabipur
Description: Rabipur is a licensed rabies vaccine.
Study: NCT04983784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care
Study: NCT03013205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study: NCT04469374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jumping exercise
Description: Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance exercise (sham control)
Description: Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
Study: NCT04982159

Intervention type: OTHER
Intervention: There is no intervention. This is an observational study.
Description: There is no intervention. This is an observational study.
Study: NCT04464668

Intervention type: BEHAVIORAL
Intervention: Provider Tools
Description: Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.

Intervention type: BEHAVIORAL
Intervention: Provider Tools
Description: Providers will be trained to use Electronic Medical Record (EMR) tools and prompts, and an organization wide cancer control champion will be trained to motivate providers and navigate patients.
Study: NCT04461132

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymphatic drainage (MLD)
Description: MLD vith vodder technique was applied to leg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin Care
Description: Wound was cleaned with salin and covered by dressing without including active products

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Skin Care
Description: Wound was cleaned with salin and covered by dressing without including active products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: breathing and foot pump exercise was prescribed

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: breathing and foot pump exercise was prescribed
Study: NCT03357289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mix vaccine
Description: Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Study: NCT03849495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-370
Description: Test drug
Study: NCT04461132

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Shame Manual Lymphatic drainage
Description: manual lymphatic drainage was applied with light touch instead of real mld techniques
Study: NCT03996551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ExeRTiOn online resource
Description: This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
Study: NCT02938520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) tablet
Description: It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) tablet
Description: It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose.
Study: NCT04464668

Intervention type: BEHAVIORAL
Intervention: Provider surveys
Description: Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)

Intervention type: BEHAVIORAL
Intervention: Provider surveys
Description: Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
Study: NCT03085901

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precizon toric intraocular lens
Description: Phacoemulsification and implantation of Precizon toric intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis toric intraocular lens
Description: Phacoemulsification and implantation of Tecnis toric intraocular lens
Study: NCT03386656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amchafibrin
Description: Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo
Study: NCT01525927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Chemotherapy for three cycles prior to radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Chemotherapy for three cycles prior to radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced dose radiotherapy
Description: Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
Study: NCT04640207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facial skin treatment
Description: Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
Study: NCT02393573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients will take metformin for two weeks before Surgery and 2 days after the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
Study: NCT02977013

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-Xa assay
Description: Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
Study: NCT03331666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evolocumab
Description: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
Study: NCT01200615

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wording of the explenation on side-effects as part of the informed consent.
Description: Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wording of the explenation on side-effects as part of the informed consent.
Description: Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wording of the explenation on side-effects as part of the informed consent.
Description: Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
Study: NCT04638712

Intervention type: OTHER
Group type: OTHER
Intervention: Microbiopsy sample
Description: before and after chemotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Microbiopsy sample
Description: before and after chemotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level
Description: before and after chemotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level
Description: before and after chemotherapy
Study: NCT05108220

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.
Study: NCT00877669

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of the prostate
Description: Standard transurethral resection of the prostate using electrocautery loop

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of the Prostate
Description: HoLEP using 100W Ho:YAG laser
Study: NCT04287101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-operative PT and OT
Description: Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative PT and OT
Description: Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
Study: NCT04301921

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional punkcture site and No anticoagulation
Description: Traditional punkcture site and No anticoagulation

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional punkcture site and ACT-guided anticoagulation
Description: Traditional punkcture site and ACT-guided anticoagulation
Study: NCT01722487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
Study: NCT01450046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-Tocotrienol
Description: Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
Study: NCT00670397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: IV
Study: NCT02675894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cooled-wet electrode
Description: RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: separable clustered electrode
Description: RFA is performed using separable clustered electrode in switching monopolar mode.
Study: NCT03849495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-370
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745
Description: Reference drug
Study: NCT02856685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
Study: NCT01724983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study: NCT02598466

Intervention type: DRUG
Intervention: Abatacept
Study: NCT03849495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745
Description: Reference drug
Study: NCT04981015

Intervention type: DIAGNOSTIC_TEST
Intervention: Three-day bladder diary
Description: A three-day bladder diary for recording voiding-flow pattern of a women
Study: NCT01462058

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 70µg Vitamin D3, daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily, 12 weeks
Study: NCT02938520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir - Injectable Suspension (CAB LA)
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine - Injectable Suspension (RPV LA)
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Study: NCT04411212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte colony-stimulating factor and platelet-rich plasma group
Description: Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
Study: NCT01985269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home visits
Description: The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
Study: NCT04373590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
Study: NCT02750072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrapatellar Approach
Description: Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprapatellar Approach
Description: Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
Study: NCT00487708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Study: NCT03745131

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw to obtain serum to determine anti-orthopox antibody titres.
Study: NCT00748150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
Description: 1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
Study: NCT04992156

Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib 125mg/d
Study: NCT01266265

Intervention type: DRUG
Intervention: inhaled prostacyclin
Description: Tyvaso

Intervention type: DRUG
Intervention: inhaled prostacyclin
Description: As prescribed by the physician

Intervention type: DRUG
Intervention: prostacyclin
Description: As prescribed by the physician

Intervention type: DRUG
Intervention: subcutaneous and intravenous prostacyclin
Description: As prescribed by physician

Intervention type: DRUG
Intervention: oral ERA
Description: As prescribed by physician

Intervention type: DRUG
Intervention: oral PDE5 inhibitors
Description: As prescribed by physician